Sight Sciences $276 million IPO
Davis Polk advised the representatives of the several underwriters in connection with an initial public offering of 11,500,000 shares of common stock of Sight Sciences, Inc. at $24.00 per share (which includes the exercise in full by the underwriters of their option to purchase up to 1,500,000 additional shares), for total gross proceeds of $276 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “SGHT.”
Based in Menlo Park, California, Sight Sciences is a growth-stage medical device company focused on the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases. The company’s product portfolio features the OMNI Surgical System and the TearCare System, which are pioneering new treatment paradigms for glaucoma and dry eye disease.
The Davis Polk corporate team included partner Alan F. Denenberg and associates Sarah Masako Kirk and Julia Molo. The intellectual property and technology transactions team included partner David R. Bauer and associates Christopher C. Woller and David A. Frey. The tax team included counsel Kiara L. Rankin and associate Dov Sussman. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices.